300347 泰格醫藥
按盤價 
56.220 +0.430 (+0.771%)
56.220 +0.430 (+0.771%) | 2024/09 - 九個月 人民幣(K¥) | 與去年同期 比較 | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | 2021/12 人民幣(K¥) | 2020/12 人民幣(K¥) | ||
| 營業總收入 | 5,067,615 | -10.32% | 7,384,039 | 7,085,471 | 5,213,538 | 3,192,279 | |
| 減：營業總成本 | 4,026,551 | -2.79% | 5,554,125 | 5,156,544 | 3,637,765 | 2,420,862 | |
| 其中:營業成本 | 3,097,333 | -8.12% | 4,535,511 | 4,277,008 | 2,942,883 | 1,678,036 | |
| 財務費用 | 31,371 | -129.66% | (108,324) | (158,124) | (216,363) | 88,052 | |
| 資產減值損失 | (10,657) | -9.41% | (29,725) | (2,416) | (12,915) | 5,414 | |
| 公允價值變動收益 | (34,412) | -104.84% | 352,771 | 535,857 | 1,815,390 | 1,137,889 | |
| 投資收益 | 109,158 | -14.54% | 338,175 | 102,751 | 312,283 | 283,773 | |
| 其中：對聯營企業和合營企業的投資收益 | -- | -- | 105,183 | 39,763 | 14,348 | (3,508) | |
| 營業利潤 | 1,084,996 | -53.07% | 2,486,941 | 2,582,399 | 3,696,967 | 2,222,312 | |
| 利潤總額 | 1,087,065 | -53.03% | 2,488,533 | 2,585,377 | 3,684,566 | 2,218,707 | |
| 減：所得稅費用 | 183,929 | -35.83% | 338,606 | 313,652 | 292,864 | 189,707 | |
| 淨利潤 | 903,135 | -55.46% | 2,149,927 | 2,271,725 | 3,391,702 | 2,029,001 | |
| 減：非控股權益 | 89,707 | -39.49% | 125,077 | 265,173 | 517,539 | 279,226 | |
| 股東淨利潤 | 813,429 | -56.72% | 2,024,850 | 2,006,552 | 2,874,163 | 1,749,775 | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.940 | -56.68% | 2.340 | 2.320 | 3.310 | 2.200 | |
| 每股派息 (元) * | -- | -- | 0.568 | 0.550 | 0.500 | 0.300 | |
| 每股淨資產 (元) * | 24.354 | 0.89% | 24.102 | 22.447 | 20.774 | 18.474 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 30/12/2024 11:04 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
